REPLY
10.1.2022 16:32:13 CET | Business Wire | Press release
REPLY [MTA, STAR: REY] strengthens its presence on the US market with the double acquisition of Enowa LLC (www.enowa.com ) - a company specialized in consulting and development of solutions based on SAP technology - and The Spur Group (www.thespurgroup.com ) - a leader in strategy consulting for marketing and sales.
Enowa LLC, headquartered in Philadelphia, is a leader in the fields of cloud design and value-added services on SAP technology and counts among its customers some of the main North American names in the space of Industrial Chemical, Consumer Services, Healthcare and Energy.
The Spur Group, based in Bellevue (Seattle), supports the main Tech Giants and global brands - including Cisco, Microsoft, Rockwell Automation, Qlik and VMWare - in defining go to market and positioning strategies combining skills in strategy, marketing, data analysis and operating models.
The investments in Enowa LLC and in The Spur Group, which together employ over 400 people, are part of Reply's international growth strategy, particularly in the United States, where Reply is already present in Atlanta, Chicago, Detroit, Kansas City, Seattle, and St. Louis.
The founders of Enowa LLC and The Spur Group with the role of "Partner Reply" will have the task of developing the activities of their respective companies within the Reply Group in North America.
"Enowa and The Spur Group - said Mario Rizzante, President of Reply - are both characterized by a great entrepreneurial spirit and constant attention to technological innovation. Thanks to the strong complementarity of their services with our current offer, we will create an optimal platform that will allow Reply to further develop its footprint in the United States, the most important world market for IT services."
Ali Sarraf, CEO of Enowa LLC commented: "We are very excited to be joining Reply’s network of companies as the leading SAP Consulting practice in North America. The strong interest in people, culture and customer focus that characterize Reply fit perfectly with our corporate culture. Together we will have the opportunity to bring new value to our customers."
"I’m thrilled to announce The Spur Group is joining Reply a company that shares the same focus on great experiences for its people and customers. - stated Randy Karr CEO of The Spur Group - We bring to Reply US network a set of unique capabilities, including strategic business consulting and go-to-market expertise. Reply has existing business in many different markets, current relationships with many of our targeted customers, standard processes and structures we can tap into, and a pool of capabilities we can now access. As a company, we are now stronger than we have ever been."
REPLY
Reply [MTA, STAR: REY, ISIN: IT0005282865] is specialized in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly focused companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
ENOWA LLC
Enowa is an SAP consulting company established in 2002 with a dedicated focus on business process and SAP consulting. With almost 20 years of experience, Enowa is an SAP Gold partner with recognized expertise in various industries executing domestic and global transformative projects. Enowa’s clients enjoy the expertise of certified, industry-leading experts, who understand their industry, business complexities and unique culture. Enowa’s consistency in delivering successful projects results in long-lasting, trusted relationships at all levels of our client’s organization. Please visit www.enowa.com
for more information.
THE SPUR GROUP
The Spur Group is the leading provider of end-to-end go-to-market services. We turn customer, partner, and employee experiences into competitive advantages by helping our clients gain actionable insights, strengthen customer engagements, improve partner leverage, fuel execution excellence, and grow revenues faster. www.thespurgroup.com
This press release is a translation, the Italian version will prevail.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005608/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom